Yesterday, Merck (NYSE:MRK) reported data from Keytruda in combo with chemotherapy for patients with non-small cell lung cancer (NSCLC). The data was positive …
Rosenblatt’s Hans Mosesmman offers a slew of reasons he continues to bet against INTC ahead of its quarterly print.
It’s been a rough few weeks for social media giant Facebook (NASDAQ:FB). As we discussed just a few weeks ago, the company has been …
Goldman Sachs’ Toshiya Hari now braces for 4% downside potential for AMD shares.
Goldman Sachs’ analyst David Tamberrino now looks for a sharp 36% downside for Tesla shares.
Expert voices across the Street point to warning flags mounting around the TSLA narrative; here’s why.
Shopify (NYSE:SHOP) and Facebook (NASDAQ:FB) have been in an unholy alliance for years – in which Facebook has shared your personal information with Shopify …
Alex Arfaei notes he continues to be the “lone bear” on this biotech player- especially after lead pipeline asset Rova-T is no longer looking at quick approval.
What do you do when a company has “more debt than assets?” Maxim’s Jason Kolbert just lost patience with MNKD.
BTIG’s Mark Palmer likewise is not swayed by the Bitcoin craze, believing investors are “overly” confident in its impact on SQ stock.